Issue Archive

Leukemic blasts in a patient with BCR-ABL1–positive acute lymphoblastic leukemia at initial diagnosis and at time of relapse after blinatumomab treatment (bone marrow smears after Pappenheim's staining and flow cytometry plots gated on blasts). The blasts after blinatumomab treatment were distinct from blasts at diagnosis with regard to morphology and immunophenotype and did not express surface CD19 anymore. Furthermore, they were negative for CD10, cyCD79a, CD34, and TdT, and expressed the myeloid antigens CD13, CD33 and CD117. See the article by Nagel et al on page 2027.